New Job Opportunity

December 24, 2025 | New Job Opportunity

Fujifilm Accelerates Biopharma Manufacturing with New Japan CDMO Facility

FUJIFILM Corporation announced the completion of one of Japan’s largest bio CDMOfacilities (the new plant) at the Toyama Second Factory of FUJIFILM Toyama Chemical and held a completion ceremony to mark the occasion. The new plant is the company’s first antibody drug manufacturing plant in Japan and is scheduled to be operational in 2027. Together with an adjacent plant currently under construction, Fujifilm will establish end-to-end manufacturing services covering drug substance manufacturing through finished goods and packaging, serving as the company’s bio CDMO hub in Asia. The new plant is equipped with 2 x 5,000 liters (L) mammalian cell culture bioreactors, which are among the world’s largest single-use bioreactors, as well as 2 x 2,000 L bioreactors. To ensure high quality and faster technology transfer between sites while reducing construction lead time, the facility adopts the “kojoX™” modular facility design approach, which standardizes equipment and quality management systems with the FUJIFILM Biotechnologies’ site in the UK. Fujifilm is establishing a globally competitive bio CDMO site in Japan that enables rapid and efficient contract manufacturing of biopharmaceuticals, such as antibody drugs and antibody-drug conjugates (ADCs). This new site leverages FUJIFILM Toyama Chemical’s aseptic manufacturing expertise, cultivated through injectable antibiotic production, and combines it with the expertise of FUJIFILM Biotechnologies, which operates bio CDMO services in Europe and the U.S. In Japan, demand for biopharmaceuticals continues to grow, yet many pharmaceutical companies outsource manufacturing to overseas, creating challenges in the speed of process development and technology transfer. To address these issues, Fujifilm is building a manufacturing facility in Japan that meets rigorous global quality standards, aiming to reduce the burden of technology transfer caused by language and geographical barriers, accelerate market launch, and contribute to a stable supply of biopharmaceuticals. The new plant, together with an adjacent plant under construction for mRNA therapeutics and vaccines, has been selected by Japan’s Ministry of Economy, Trade, and Industry for the project of “Developing Biopharmaceutical Manufacturing Sites to Strengthen Vaccine Production.” This dual-use designation will allow the facility to manufacture biopharmaceuticals during normal times and switch to vaccine production in the event of a pandemic.

December 22, 2025 | New Job Opportunity

Samsung Biologics Acquires U.S. Facility From GSK, Securing 500+ Jobs

Samsung Biologics, a leading contract development and manufacturing organization, announced that its wholly owned U.S. subsidiary, Samsung Biologics America, has entered into a definitive agreement to acquire 100% of Human Genome Sciences from GSK . This strategic move secures Samsung Biologics' first U.S.-based manufacturing site, a significant expansion of the company's global footprint and its long-term commitment to the U.S. market. Existing products will continue to be manufactured at the site, and Samsung Biologics plans to make additional investments to expand the site's capacity and upgrade technology to further support a more resilient U.S. supply chain for critical biologic medicines. Under the terms of the agreement, with closing anticipated toward the end of Q1 of 2026, Samsung Biologics will acquire the Rockville assets for USD 280 million. The company will also retain more than 500 employees at the site to ensure operational continuity and stability. By integrating this facility into our global network, Samsung Biologics will provide clients with flexible, multi-site options in both the U.S. and Korea to ensure that live-saving therapeutics are reliably available to American patients. Samsung Biologics has established a proven track record of operational and construction excellence through on-time completion of its Bio Campus I and II, and also recently secured land for Bio Campus III, which will house distinct R&D and manufacturing programs for new modalities. With 785,000 liters of capacity across five plants, the industry's leading capacity, Samsung Biologics continues to advance its diversified portfolio spanning monoclonal antibodies, antibody-drug conjugates (ADCs), mRNA, organoid-based services, and next-generation therapies. "This landmark acquisition is a testament to our unwavering commitment to advancing global healthcare and bolstering our manufacturing capabilities in the U.S. The investment will enable us to deepen our collaboration with federal, state, and local stakeholders to best serve our customers and partners while ensuring a reliable and stable supply of life-saving therapeutics," said John Rim, CEO and President of Samsung Biologics. "This marks an important step forward in our mission to achieve a better life through biomedicines, and we look forward to building on the legacy of this facility as we welcome experienced colleagues to the Samsung Biologics family and continue delivering innovative solutions that make a meaningful impact." Regis Simard, President, Global Supply Chain, GSK, said: "Today's agreement to divest the Rockville manufacturing site to our valued long-term partner, Samsung Biologics, will secure the manufacture of two important medicines on US soil for US patients and further build GSK's supply chain resilience. Along with GSK's recent commitment to invest $30bn in R&D and manufacturing in the US over the next 5 years, this deal enables us to further focus on building the agility, capacity and capability needed in our manufacturing network to deliver the next generation of specialty medicines and vaccines. I am confident in a positive partnership and future for the Rockville site." 

December 19, 2025 | New Job Opportunity

Identiv Completes Manufacturing Transition to Thailand, Strengthens Leadership in Advanced IoT Manufacturing

Identiv, Inc. a global leader in RFID- and BLE-enabled Internet of Things (IoT) solutions, announced the successful completion of its manufacturing transition from Singapore to its state-of-the-art facility in Bangkok, Thailand. The successful production transition to Thailand represents a significant achievement for the Perform pillar of Identiv's Perform, Accelerate, Transform (P-A-T) strategy, establishing a state-of-the-art and highly efficient manufacturing operation in a location known for its strong workforce and competitive cost structure. This strategic milestone is expected to drive operational excellence, while also positioning the company as an IoT industry leader in Multicomponent Manufacturing (MCM), the forward-looking production method critical for the next decade of advanced IoT applications. "The completion of our Thailand production transition is a foundational milestone for Identiv as a pure-play IoT company, marking the end of a successful two-year process and delivering on a key strategic objective for operational excellence," said Kirsten Newquist, CEO at Identiv. "By providing a state-of-the-art, high-quality and cost-efficient base, the Thailand facility is now the engine of our competitive advantage, engineered for the future of IoT and sustained, profitable growth." The Strategic Advantage of MCM at IdentivAs IoT applications expand from inventory management and asset tracking to complex, high-value applications such as real-time location tracking, condition monitoring, and advanced security, simple, single component inlays are evolving into more sophisticated, multi-component designs to deliver this data accurately and consistently. MCM is an important production method for this new era of IoT manufacturing, enabling the industrial-scale integration of various components, including chips, sensors, and batteries, into advanced RFID- and BLE-enabled tags. Identiv's Thailand facility is strategically positioned with this advanced MCM capability, enabling the Company to rapidly commercialize next-generation, high-value IoT solutions and support continued growth. "Multicomponent manufacturing is not merely an assembly method; it is the orchestration of interdependent disciplines, including product design, process engineering, material science, and testing," said Dr. Manfred Mueller, Chief Strategy Officer at Identiv. "The decade of experience our teams have in refining these parameters across thousands of production runs is a key competitive advantage for Identiv. This expertise is what allows us to rapidly prototype and commercialize complex systems for critical high-value applications, cementing our role as the infrastructure layer shaping IoT's future."

December 18, 2025 | New Job Opportunity

Alnylam’s $250M Massachusetts Expansion to Create Jobs, Strengthen Global Life Sciences Hub

Alnylam Pharmaceuticals, Inc. the leading RNAi therapeutics company, announced the planned expansion of its state-of-the-art manufacturing facility in Norton, Massachusetts. The Company is preparing to invest $250 million to advance what is poised to become the industry’s first fully dedicated, proprietary, siRNA enzymatic-ligation manufacturing facility. This investment is expected to meaningfully expand capacity, significantly reduce production costs, and position Alnylam to support future launches across its growing pipeline of potential new medicines. As part of the expansion, Alnylam also announced that this next-generation, scalable, enzymatic ligation manufacturing platform, siRELIS™, has been accepted into the U.S. Food and Drug Administration’s (FDA) Emerging Technology Program, accelerating dialogue with global health authorities on innovative manufacturing approaches for oligonucleotide-based medicines. This acceptance follows successful demonstration of Alnylam’s enzymatic ligation platform through production of pilot-scale batches of zilebesiran, which is being studied to reduce the risk of major adverse cardiovascular events in patients with hypertension (high blood pressure), and nucresiran, which is in development for the treatment of transthyretin-mediated amyloidosis (ATTR). “At this pivotal time with our expanding pipeline of RNAi therapeutics, Alnylam is accelerating development of siRNA manufacturing and changing what’s possible in a single facility,” said Yvonne Greenstreet, M.D., MBA, Chief Executive Officer of Alnylam. “This advance will be a critical enabler in the scaling of our pipeline to include potential treatments for diseases such as hypertension, type 2 diabetes, and obesity.” Expansion in Norton, MAThe $250 million expansion of Alnylam’s 200,000 sq. ft. Norton facility will increase its capabilities to locally produce both clinical and commercial supply of siRNA oligonucleotide drug substance for patients around the world. The facility, which opened in 2021, has played a key role in the growth of Alnylam’s clinical pipeline and acts as a pipeline accelerator for early-stage programs, including programs targeting different tissue types (e.g., liver, CNS, muscle, adipose, etc.). This expansion will strengthen Massachusetts’ position as a global hub of life sciences innovation. Construction is underway, with new capabilities expected to become fully operational by late 2027. “Alnylam represents the world-class health care innovation Massachusetts is known for. Alnylam has been a leader in life sciences in our state for over two decades,” said Governor Maura Healey. “Their scientific breakthroughs in siRNA manufacturing have transformed care by providing RNAi therapeutics to people who need it most, while creating thousands of jobs across our state. We're excited to support their growth through the expansion of a manufacturing facility in Southeastern Mass., and we're grateful for their continued investment in Massachusetts.” “Alnylam’s continued investment in Massachusetts underscores the Commonwealth’s role as a global leader in biomanufacturing,” said Dr. Kirk Taylor, President and CEO of the Massachusetts Life Sciences Center (MLSC). “This expansion will bring high-quality jobs to this area and ensure patients worldwide have the opportunity to benefit from medicines made right here in Massachusetts. We look forward to deepening our partnership as we work together to advance the thriving life sciences ecosystem here in the Commonwealth.” A Breakthrough in Manufacturing at ScaleAlnylam’s siRELIS™ platform builds RNAi therapeutics more efficiently using fewer materials and plant resources, and greatly expands capacity – making large-scale, sustainable production possible. “Manufacturing oligonucleotide-based medicines is highly complex, and the current manufacturing technology will struggle to meet increased demand. We have successfully applied a reproducible, less time-intensive process that increases throughput while maintaining the highest quality standards,” said Timothy Maines, Chief Technical Operations and Quality Officer at Alnylam. “The expansion of our Norton facility presents an opportunity to reinvent what’s possible in oligonucleotide manufacturing.”

December 17, 2025 | New Job Opportunity

NCOG BioPharma to add nearly 1,000 jobs through $200M manufacturing expansion

INCOG BioPharma Services, a leading contract development and manufacturing organization (CDMO), announced another major expansion with an investment of approximately $200 million in its manufacturing facility in Fishers, Indiana. This investment will significantly increase the company's injectable drug product manufacturing capacity. By 2030, INCOG expects to employ nearly 1,000 people at its Fishers campus. These high-paying, high-value jobs are set to establish INCOG as one of the preeminent employers within Indiana's life sciences industry. "The continued demand from our global biopharma partners and our team's ability to deliver create the opportunity for this next level of investment and expansion," said Cory Lewis, CEO of INCOG BioPharma. "Committing another $200 million and employing nearly 1,000 team members by 2030 underscores our dedication to continue providing world-class, flexible manufacturing capacity while creating generational opportunities for the talented workforce here in central Indiana. This is a vote of confidence in our team, our quality, and our future." The accelerated investment is made possible by incentives offered by the State of Indiana. "INCOG BioPharma's expansion is yet another example of Indiana leading in life sciences and advanced manufacturing. This major investment further positions us as one of the nation's top hubs for innovative drug development and will bring hundreds of new, high-paying jobs to our state. I'm proud to see companies like INCOG choose Indiana as the place to grow," said Indiana Governor Mike Braun. The expansion is scheduled to begin in early 2026, establishing the 21‑acre campus as a premier global manufacturing hub for injectable biopharmaceuticals, with approximately 300,000 square feet of purpose‑built space. This investment also reinforces the long-standing partnership between INCOG BioPharma and the City of Fishers, anchoring the company's growth in the region. "In 2020, we committed to doubling down to make Fishers a life science hub. INCOG believed in our vision, and as they bring their third expansion to Fishers, we have delivered promises made to our community. Fishers is leading the state as an ideal home for life science firms, with more than $1 billion in investment committed across life science firms who call our city home," said Scott Fadness, Mayor of Fishers. "This massive new investment and the commitment to nearly 1,000 high-paying jobs will have a transformative impact on our community's economic landscape for decades to come. We are proud to support their mission to bring critical therapies to the world."

December 12, 2025 | New Job Opportunity

ProPharma Expands Global Footprint with New Hyderabad Office Launch

ProPharma, the leading global provider of regulatory, clinical, and compliance services for the life sciences industry and a portfolio company of Odyssey Investment Partners, announced the official inauguration of its new office in Hyderabad, India. Strategically located in Mindspace, at the heart of Hyderabad's technology corridor (HITEC City/Madhapur), the new office places ProPharma among the world's leading Global Capability Centers (GCCs) in the pharmaceutical industry. Mindspace is also the first commercial business park in Hyderabad to receive a Gold rating from the Indian Green Building Council (IGBC). The prominent placement of the ProPharma logo atop the building underscores the company's growing presence and brand visibility in India. The expansion supports ProPharma's continued growth trajectory by providing capacity for additional team members across multiple service lines and creating a modern, collaborative environment designed to inspire innovation and connection. More than 70 employees participated in the inaugural celebration. "This milestone represents an important step forward in ProPharma's global expansion," said Jason DeGoes, President, ProPharma. "Our new Hyderabad office strengthens our ability to deliver high-quality, integrated solutions for our clients around the world and reflects our commitment to building an exceptional environment for our teams." "We're proud to establish a world-class workspace in Hyderabad—one designed to foster creativity, efficiency, and collaboration," added Pavan Hemadri, Director of Business Operations, ProPharma. "This move enhances our ability to attract top local talent and better serve our clients across regulatory, clinical, and compliance domains." The new state-of-the-art facility features open, collaborative workspaces aligned with ProPharma's global culture of innovation and operational excellence. It also underscores ProPharma's long-term investment in India as a key hub supporting its worldwide operations.

December 11, 2025 | New Job Opportunity

Onkos Surgical Launches NJ Innovation Center to Expand Chemist and Engineering Roles

Onkos Surgical, a leading provider of innovative solutions for complex orthopaedic procedures, has opened the NanoCept Innovation Center, a new facility in Bridgewater Township, NJ. Located in the New Jersey Center of Excellence Campus, the new 4,600-square-foot facility will allow the company to bring a full innovation process in-house for its flagship NanoCept® Antibacterial Technology, the first ever orthopaedic antibacterial coating commercially available on the U.S. market. The product offers a proactive approach against intraoperative bacterial contamination, a crucial advancement in the field of orthopaedic implants. The production capacity expansion will allow the company to meet a growing demand for the NanoCept technology from surgeons and hospitals. "Onkos is proud to have worked with the FDA to bring to market the first antibacterial coating technology. The opening of the NanoCept Innovation Center marks another important milestone in our company's journey," said Patrick Treacy, Founder and CEO. "This investment will allow us to get this groundbreaking technology into the hands of more surgeons, faster, and it puts us in a position to help more patients with complex orthopaedic conditions." "I am excited by Onkos' commitment to bring this technology to more implants and ultimately to more patients," said Steven Gitelis, MD, Director of Rush University/MD Anderson's Orthopaedic Oncology Program and Chief Medical Officer of Onkos. "This is a unique technology that arms us, as surgeons, with a powerful solution to help mitigate the serious issue of bacteria in the operating room." Onkos Surgical's commitment to the New Jersey region Opening the new facility in Bridgewater underscores Onkos Surgical's strong commitment to the region. The NanoCept Innovation Center will employ a team of chemists, engineers, and technicians in the new facility to lead its innovation operations. The company's headquarters are located at 77 East Halsey Road in Parsippany, NJ. "The opening of the NanoCept Innovation Center in Bridgewater exemplifies the cutting-edge innovation that defines New Jersey's 7th Congressional District," said Congressman Tom Kean, Jr. "Advancements like those being pursued by Onkos Surgical have the potential to drive meaningful progress in patient care and expand possibilities in modern medicine. Congratulations to Onkos on this remarkable milestone."

December 10, 2025 | New Job Opportunity

$6B Eli Lilly Investment Brings 450 High-Skill Jobs to Huntsville

Eli Lilly and Company announced plans to invest more than $6 billion in a new manufacturing facility in Huntsville, Alabama. This next-generation synthetic medicine active pharmaceutical ingredient (API) facility, the third of four new U.S. sites Lilly plans to announce, will produce small molecule synthetic and peptide medicines. Importantly, the site will be among those that will manufacture orforglipron, Lilly's first oral, small molecule GLP-1 receptor agonist, which the company expects to submit to global regulatory agencies for obesity by the end of this year. Lilly will bring 450 high-value jobs to the area, including engineers, scientists, operations personnel and lab technicians. Construction, expected to begin in 2026, is anticipated to generate 3,000 construction jobs as the state-of-the-art facility is built. Completion is expected in 2032. "Huntsville's track record of science and innovation, supported by advanced manufacturing expertise and a skilled workforce, makes Alabama an ideal location for Lilly to expand domestic manufacturing capacity for next‑generation medicines," said David A. Ricks, Lilly chair and CEO. "Today's investment continues the onshoring of active pharmaceutical ingredient (API) production, strengthening supply chain resilience and reliable access to medicines for patients in the U.S." Expanding Lilly's U.S. manufacturing presence in Alabama will boost the Huntsville economy. For every dollar Lilly invests there, it estimates up to four dollars in additional local economic activity. Also, for each manufacturing job created, several more will be generated in related sectors like supply chain, logistics and retail. "Huntsville and our entire state have a proven legacy of innovation, and there is no better home for Lilly than right here in Alabama. Our roots in the biosciences industry run deep, and Alabama's contributions to this burgeoning sector continue," said Kay Ivey, Governor of Alabama. "We are proud to welcome Lilly's new U.S. manufacturing facility, which we are thrilled is the largest initial investment in our state's history. No doubt, Alabamians will help Lilly do things that have never been done before, and we will ensure this great company achieves their mission of improving the health and well-being of people all around the country and globe." The Greenbrier South, Huntsville, Alabama site was selected from more than 300 applications, partly based on its proximity to the HudsonAlpha Institute for Biotechnology, an established bioscience campus that supports workforce training and research. In addition to its workforce potential, the region offers ready access to utilities, transportation and favorable zoning and incentives. Lilly plans to use state-of-the-art technologies, including machine learning, AI, digitally integrated monitoring systems and advanced data analytics to drive right-first-time execution. Digital automation will be embedded throughout the site to streamline operations and ensure a reliable supply of safe, high-quality medicines. "By establishing this new facility, Lilly is deepening America's expertise in advanced chemical synthesis and setting new standards for sustainable manufacturing," said Edgardo Hernandez, executive vice president and president of Lilly Manufacturing Operations. "Our investment not only expands our technical capabilities but also reinforces our commitment to environmental stewardship, leveraging innovative processes to minimize waste and achieve carbon neutrality. Each step forward strengthens our U.S. operations and supports healthier communities for the future."

December 09, 2025 | New Job Opportunity

Global Life Sciences Industry Accelerates Expansion, Driving Tens of Thousands of New Jobs Across Biopharma, MedTech, and Healthcare Delivery

The global life sciences industry is undergoing one of its most significant expansion cycles in recent years, with major pharmaceutical, biotech, MedTech, and healthcare organizations announcing multi-billion-dollar investments, new manufacturing sites, and large-scale workforce growth across key markets. From the United States and Europe to Asia and the Middle East, companies are scaling operations to meet rising demand for advanced therapies, strengthen supply chain resilience, and expand access to critical healthcare innovations. Collectively, these initiatives will create tens of thousands of jobs over the coming decade while deepening regional innovation ecosystems. U.S. Sees Major Biomanufacturing Momentum In the United States, several leading companies have unveiled transformative expansions that reinforce the country’s leadership in biomanufacturing and advanced therapies. Thermo Fisher Scientific inaugurated its East Coast flagship Advanced Therapies Collaboration Center in Philadelphia, strengthening nationwide support for the development of next-generation cell and gene therapies. The center provides biotech and translational researchers with access to expert scientific guidance, cutting-edge technologies, and scalable process development infrastructure. AstraZeneca announced a landmark $2 billion investment in Maryland, expanding its Frederick biologics facility and building a new site in Gaithersburg. Together, the projects will support 2,600 jobs, including 300 newly created high-skill roles, while nearly doubling biologics manufacturing capacity and strengthening the company’s rare disease portfolio. Moderna is investing $140 million to onshore drug product manufacturing to its Norwood, Massachusetts campus, completing a fully end-to-end U.S. manufacturing loop for mRNA medicines. This expansion enhances domestic production and supports new job creation as the company advances its pipeline across infectious disease, oncology, rare diseases, and autoimmune therapies. Novartis is planning a major expansion in North Carolina, establishing a flagship U.S. manufacturing hub with end-to-end capabilities for key medicines. The investment — part of the company’s broader $23 billion U.S. infrastructure commitment — is expected to create 700 direct jobs and over 3,000 indirect jobs by 2030, strengthening the resilience of the national pharmaceutical supply chain. Armata Pharmaceuticals announced the commissioning of its new cGMP phage-therapy manufacturing facility in Los Angeles — a crucial step that supports domestic production of innovative bacteriophage therapeutics and aligns with federal priorities to localize essential medicine manufacturing. Cencora is investing $1 billion through 2030 to reinforce its U.S. pharmaceutical distribution network, including new centers in Ohio, Alabama and California. This expansion will enhance nationwide logistics capabilities and support future job creation as demand for specialty pharmaceuticals grows. Avantor opened a new Centralized Service Center in the Greater Boston area, enabling regional research laboratories to reclaim critical wet lab space by offloading essential but non-core operations. The facility is expected to streamline workflow efficiency for biotech and academic organizations in one of the world’s most active scientific hubs. Asia-Pacific Emerges as a High-Growth Life Sciences Engine Asia continues to see rapid industrial and healthcare growth, with significant investments in manufacturing, diagnostics, and talent development. In South Korea, Vieworks has doubled its production capacity with a major expansion of its Hwaseong manufacturing campus, strengthening global supply of digital X-ray detectors and industrial imaging systems. AIRS Medical is rapidly growing its footprint across Europe, the Middle East, and Africa as demand accelerates for its AI-driven MRI acceleration technology, SwiftMR™ — reinforcing Korea’s leadership in AI-powered diagnostics. In India, Sai Life Sciences began construction of its advanced CMC Process R&D Center in Hyderabad. Scheduled for completion in 2026, the 100,000-sq-ft facility will double process R&D capacity and add new capabilities in peptides, oligos, formulation, and early clinical supplies. This investment positions the company as a preferred integrated drug development partner for global innovators. Singapore is also seeing rapid scale-up, with Almac Group announcing a significant expansion of its Singapore facility as part of its long-term APAC strategy. The investment will boost clinical supply management capabilities and support the region’s growing demand for temperature-controlled and cold-chain clinical operations. Malaysia's healthcare sector is set to benefit from the launch of the RM500 million Tunku Laksamana Johor Cancer Centre and Hospital, which will create 1,000 jobs and strengthen regional oncology services. The facility will house Southeast Asia’s first cyclotron outside the Klang Valley, enhancing radiopharmaceutical production capacity. In China, Mölnlycke has initiated construction of its first local wound care manufacturing site in Changshu. The facility — designed to global standards — will begin production by 2026–2027 and create new local jobs while improving supply chain resilience for advanced wound care products. Europe Sees Strong Pharmaceutical and Manufacturing Growth European life sciences manufacturing is experiencing a new wave of investment focused on strengthening regional supply chains. Eli Lilly announced a €3 billion (USD $3B) manufacturing facility in the Netherlands, located in the Leiden Bio Science Park. The site will support oral medicines across cardiometabolic diseases, neuroscience, immunology, and oncology. The investment will create 2,000 jobs including 500 long-term high-wage positions and 1,500 construction jobs. Switzerland-based Jungbunzlauer completed its acquisition of a manufacturing site in Illinois — its first U.S. facility — supporting local job creation and enhancing North American supply capability for high-quality ingredients used across food, pharmaceuticals, and personal care. Strengthening Essential Medicine and Antibiotic Supply Chains In South Korea, Boryung commenced the expansion of its penicillin production facility at the Ansan Campus to fortify national antibiotic supply security. With oral penicillins designated as essential medicines, the upgraded site will introduce advanced automation and digital transformation technologies to ensure stable production and prevent shortages during public health emergencies. Addressing Global Healthcare Talent Needs Addressing critical workforce shortages remains a global priority. In the United States, WorldWide HealthStaff Solutions announced the recruitment of over 500 internationally trained nurses for deployment across Iowa — a state facing a projected 21% shortfall in nursing supply. The new arrivals will support hospitals, long-term care centers, and rural facilities while improving nurse-to-patient ratios and reducing reliance on overtime and agency staff. A Convergence of Innovation, Manufacturing, and Talent Growth Across continents, a clear trend is emerging: companies are investing aggressively to strengthen supply chains, localize manufacturing, advance therapeutic innovation, and close widening workforce gaps. These investments will not only accelerate the development of new therapies but also strengthen regional healthcare resilience. With billions of dollars committed and thousands of new jobs set to be created globally, the life sciences sector is entering a period of unprecedented expansion. This momentum will redefine global healthcare delivery, manufacturing capabilities, and scientific innovation for years to come.

December 08, 2025 | New Job Opportunity

BorderPlus Expands Into Saudi Arabia and GCC to Strengthen Healthcare Workforce

BorderPlus, the global talent mobility platform, announced its expansion into Saudi Arabia and the wider GCC region, less than a year after launching operations. This milestone marks a major step forward in the company’s mission to build transparent, skill-first, and ethical international pathways for healthcare professionals. The GCC healthcare ecosystem is projected to require over 50,000 additional nurses by 2027, driven by rapid population growth, rising chronic disease burden, and major healthcare investments across the region. In response, BorderPlus will now partner with hospitals, long-term care operators, and medical facilities across Saudi Arabia, the UAE, Qatar, Bahrain, Kuwait, and Oman, providing structured, compliance-driven workforce solutions while ensuring migrant nurses access safe, dignified, and well- supported international career opportunities. "Our expansion into Saudi Arabia and the GCC marks a significant milestone in BorderPlus', mission to build transparent, high-quality global mobility pathways for migrant nurses,"; said Ayush Mathur, Co-Founder of BorderPlus. "The region is experiencing significant demand for skilled healthcare professionals. Our work in Germany has taught us a lot, and while the GCC presents its own challenges, we believe the same transparent, talent-first approach can work here too. This step strengthens our commitment to both sides providing hospitals with reliable talent and empowering nurses with life-changing international opportunities." “As we strengthen our presence in the GCC, we are also laying the groundwork for our next phase of global growth, extending our model to high-demand markets across Europe, the Middle East, and Asia. We are actively leveraging new age technology and AI to build a more connected mobility ecosystem for nurses and healthcare institutions”, commented, Mayank Kumar, CEO & Co-Founder, BorderPlus. BorderPlus will begin onboarding its first GCC-focused nurse cohorts starting January 2026, with multiple partnerships already underway with hospitals and long-term care providers across Saudi Arabia and the UAE. To support this expansion, the company has established an operational presence in Dubai, enabling seamless employer coordination, documentation oversight, and on-ground support for nursing professionals.

Page 1 of 47

Featured Recruiters